#USA #Mount Pleasant #Epidermolysis Bullosa #Paradigm Therapeutics #Zorblesia™

Paradigm Therapeutics Initiates Phase 3 Trial for Zorblesia™

On October 22, 2026, Paradigm Therapeutics, Inc., a clinical-stage biopharmaceutical company, made a significant announcement regarding its investigational product, SD-101, also known as Zorblesia™. This product is under development to treat the debilitating skin condition known as epidermolysis bullosa (EB). The company has successfully enrolled the first patient in its Phase 3 clinical trial, a crucial step in the advancement of this innovative treatment.

Understanding Epidermolysis Bullosa

Epidermolysis bullosa is a rare genetic disorder characterized by extremely fragile skin that can blister and tear easily, often from birth or early childhood. This challenging condition can lead to chronic wounds, severe pain, itching, infections, and scarring, greatly impacting the quality of life for patients and their families. Currently, available treatments offer limited relief, underscoring the urgent need for new therapeutic options.

The Phase 3 SD-007 Study

The Phase 3 study, referenced as SD-007, is a multicenter, randomized, double-blind, placebo-controlled trial designed to rigorously assess the safety and efficacy of Zorblesia™. The trial aims to evaluate wound closure rates, the extent of body surface area affected by wounds, and the reduction of itching in patients suffering from three major subtypes of EB: epithelial bullosa simplex (EBS), recessive dystrophic epidermolysis bullosa (RDEB), and junctional epidermolysis bullosa (JEB).

Approximately 80 patients aged between 28 days and 12 years will be recruited across 17 clinical centers in 14 countries, spanning North America, South America, Europe, Asia, and Australia. Participants will apply the topical cream as part of their daily regimen for a duration of two months. Those who complete the SD-007 study may have the opportunity to take part in a subsequent trial, SD-008, allowing continued access to treatment.

Insights from Paradigm's CEO

Dr. Robert Ryan, CEO of Paradigm Therapeutics, emphasized the pressing needs of EB patients: "Individuals with EB often endure chronic pain, itching, and recurrent infections, alongside the risk of enduring complications due to untreated wounds. Current treatment options remain far from adequate, illustrating the critical need for robust therapies designed to address the widespread skin lesions present in EB. We believe Zorblesia™ could provide a novel approach to managing this condition."

The initiation of this Phase 3 trial marks a pivotal moment in the development of Zorblesia™, with prior clinical studies supporting its hypothesis of promoting wound closure and reducing affected skin areas. Dr. Ryan stated, "We are committed to advancing this treatment to regulatory approval, thereby broadening the therapeutic options available for EB patients and their families. Our collaboration with potential partners is vital to the ongoing development and global availability of this therapy."

Support from Investors

Moreover, Dr. Fred Eshelman from Eshelman Ventures expressed his firm belief in the company’s mission: "Investing in Paradigm represents a commitment to addressing the critical challenges that EB patients face daily. Ensuring access to more treatment options is essential to improving the lives of those affected by this devastating disease."

About Zorblesia™

Zorblesia™ is designed for daily topical application, with a formulation that does not require special clinical handling, providing ease of use for both patients and caregivers. Its development has been underscored by positive outcomes from previous Phase II and III trials involving a total of 217 pediatric and adult patients suffering from various subtypes of EB. As Paradigm gains valuable insights into the efficacy and safety of Zorblesia™, they are poised to continue shaping effective treatment pathways for EB, catering to patients and families desperately seeking viable solutions.

The Future of EB Treatment

The landscape of epidermolysis bullosa treatment is evolving, with Zorblesia™ leading the charge towards more effective and accessible care. Paradigm Therapeutics remains at the forefront, not just in innovation but in the hope and relief it intends to bring for those living with this challenging condition. As they move forward with the Phase 3 trial, the potential for Zorblesia™ to transform the treatment paradigm for EB continues to grow, promising a brighter future for affected individuals.

For more information on this trial, visit Paradigm Therapeutics.